Trial reportDrug and alcohol dependence2019
Placebo-controlled randomized clinical trial testing the efficacy and safety of varenicline for smokers with HIV.
Trial report in Drug and alcohol dependence, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01710137 (A Placebo Controlled Trial of Varenicline for Smoking Among Those With HIV/AIDS), which is not on this map. Cited by 37 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Placebo Controlled Trial of Varenicline for Smoking Among Those With HIV/AIDS
Who cites it
37 citing papers in PubMed, 6 syntheses or guidelines pooled it, 46 citations in OpenAlex.
- Pooled it
- Korean Clinical Practice Guideline of Korean Society for Research on Nicotine and Tobacco (KSRNT) and National Evidence-based Healthcare Collaborating Agency (NECA) on Treatment of Tobacco Use 2024.Journal of Korean medical science · 2025Guideline
- Interventions for tobacco use cessation in people living with HIV.The Cochrane database of systematic reviews · 2024Pooled it
- Factors Influencing Tobacco Smoking and Cessation Among People Living with HIV: A Systematic Review and Meta-analysis.AIDS and behavior · 2024Pooled it
- Nicotine receptor partial agonists for smoking cessation.The Cochrane database of systematic reviews · 2023Pooled it
- Cessation classification likelihood increases with higher expired-air carbon monoxide cutoffs: a meta-analysis.Drug and alcohol dependence · 2021Pooled it
- Pilot Trial of a Behavioral Economics-Informed Clinical Decision Support Alert to Improve Inpatient Tobacco Use Treatment Rates.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2025Trial
- Effectiveness of Varenicline and Cytisine for Alcohol Use Reduction Among People With HIV and Substance Use: A Randomized Clinical Trial.JAMA network open · 2022Trial
- The effect of varenicline on mood and cognition in smokers with HIV.Psychopharmacology · 2020Trial
- A pilot study to examine the acceptability and health effects of electronic cigarettes in HIV-positive smokers.Drug and alcohol dependence · 2020Trial
- Prevalence of tobacco use in a cross-sectional survey of people initiating HIV care in a Chennai clinic.Scientific reports · 2026Article
- A qualitative investigation of tobacco use and cessation experiences among people living with HIV in Botswana.Discover public health · 2026Article
- Protocol for the Mobile behavioral support plus varenicline for tobacco cessation among people living with HIV in India (MoVIe): A hybrid implementation-effectiveness randomized trial.Contemporary clinical trials · 2026Article
- The role of alternative reinforcers in smoking outcomes among people with and without HIV.Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors · 2025Observational
- Differences in Cognition and Smoking Abstinence Rates Among People With and Without HIV Who Smoke.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2025Observational
- Design and rationale of the Botswana Smoking Abstinence Reinforcement Trial: a protocol for a stepped-wedge cluster randomized trial.Implementation science communications · 2024Article
- Intermittent theta burst stimulation and functional connectivity in people living with HIV/AIDS who smoke tobacco cigarettes: a preliminary pilot study.Frontiers in psychiatry · 2024Article
- Prevalence and trends of cigarette smoking among adults with HIV infection compared with the general population in Korea.Epidemiology and health · 2024Article
- Association of HIV Infection and Incident Abdominal Aortic Aneurysm Among 143 001 Veterans.Circulation · 2023Article
- COPD in People with HIV: Epidemiology, Pathogenesis, Management, and Prevention Strategies.International journal of chronic obstructive pulmonary disease · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundPeople living with HIV/AIDS (PLWH) smoke tobacco at higher rates and have more difficulty quitting than the general population, which contributes to significant life-years lost. The effectiveness of varenicline, one of the most effective tobacco dependence treatments, is understudied in HIV. We evaluated the safety and efficacy of varenicline for smoking cessation among PLWH.
methodsThis was a single-site randomized, double-blind, placebo-controlled, phase 3 clinical trial (NCT01710137). PLWH on antiretroviral therapy (ART) who were treatment-seeking daily smokers were randomized (1:1) to 12 weeks of varenicline (n = 89) or placebo (n = 90). All participants were offered six smoking cessation behavioral counseling sessions. The primary outcome was 7-day point prevalence abstinence, confirmed with breath carbon monoxide, at Weeks 12 and 24. Continuous abstinence and time to relapse were secondary outcomes. Safety measures were treatment-related side effects, adverse events, blood pressure, viral load, and ART adherence.
resultsOf the 179 smokers, 81% were African American, and 68% were male. Varenicline increased cessation at Week 12 (28.1% vs. 12.1%; OR = 4.54, 95% CI:1.83-11.25, P = .001). Continuous abstinence from Week 9 to 12 was higher for varenicline vs. placebo (23.6% vs. 10%; OR = 4.65, 95% CI:1.71-12.67, P = .003); at Week 24, there was no effect of varenicline for point prevalence (14.6% vs. 10%), continuous abstinence (10.1% vs. 6.7%), or time to relapse (Ps > .05). There were no differences between varenicline and placebo on safety measures (Ps > .05).
conclusionsVarenicline is safe and efficacious for short-term smoking cessation among PLWH and should be used to reduce tobacco-related life-years lost in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.